Autoimmune liver diseases and recurrence after orthotopic liver transplantation: What have we learned so far?

Transplant International

Volumn 22, Issue 2, 2009, Pages 144-152

  Schreuder, Tim C M A ^a,b   Hübscher, Stefan G ^c   Neuberger, James ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Autoimmune hepatitis; Primary biliary cirrhosis; Primary sclerosing cholangitis; Rejection; Transplantation

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID; PREDNISONE; TACROLIMUS; URSODEOXYCHOLIC ACID;

AUTOIMMUNE HEPATITIS; BILE DUCT; BILE DUCT OBSTRUCTION; COLON; COMORBIDITY; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE COURSE; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG USE; GRAFT FAILURE; GRAFT SURVIVAL; HAPLOTYPE; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LIVER BIOPSY; LIVER FUNCTION; LIVER GRAFT; LIVER HISTOLOGY; LIVER TRANSPLANTATION; ORTHOTOPIC TRANSPLANTATION; PATHOGENESIS; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK FACTOR; SEROLOGY;

AUTOIMMUNE DISEASES; HUMANS; LIVER DISEASES; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RECURRENCE;

EID: 58149293357     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2008.00729.x     Document Type: Review

References (91)

1. Rowe IA, Webb K, Gunson BK, Mehta N, Haque S, Neuberger J. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int 2008 21 : 459.
2. Neuberger J, Portmann B, Macdougall BR, Calne RY, Williams R. Recurrence of primary biliary cirrhosis after liver transplantation. N Engl J Med 1982 306 : 1.
3. Neuberger J, Portmann B, Calne R, Williams R. Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting. Transplantation 1984 37 : 363.
4. Lerut J, Demetris AJ, Stieber AC, et al. Intrahepatic bile duct strictures after human orthotopic liver transplantation. Recurrence of primary sclerosing cholangitis or unusual presentation of allograft rejection? Transpl Int 1988 1 : 127.
5. Campsen J, Zimmerman MA, Trotter JF, et al. Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl 2008 14 : 181.
6. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 2006 12 : 1813.
7. Yamagiwa S, Ichida T. Recurrence of primary biliary cirrhosis and primary sclerosing cholangitis after liver transplantation in Japan. Hepatol Res 2007 37 (Suppl. 3 S449.
8. Ayata G, Gordon FD, Lewis WD, et al. Liver transplantation for autoimmune hepatitis: a long-term pathologic study. Hepatology 2000 32 : 185.
9. Duclos-Vallee JC, Sebagh M, Rifai K, et al. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. Gut 2003 52 : 893.
10. Gonzalez-Koch A, Czaja AJ, Carpenter HA, et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 2001 7 : 302.
11. Milkiewicz P, Hubscher SG, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 1999 68 : 253.
12. Narumi S, Hakamada K, Sasaki M, et al. Liver transplantation for autoimmune hepatitis: rejection and recurrence. Transplant Proc 1999 31 : 1955.
13. Prados E, Cuervas-Mons V, de la MM, et al. Outcome of autoimmune hepatitis after liver transplantation. Transplantation 1998 66 : 1645.
14. Wright HL, Bou-Abboud CF, Hassanein T, et al. Disease recurrence and rejection following liver transplantation for autoimmune chronic active liver disease. Transplantation 1992 53 : 136.
15. Gouw AS, Haagsma EB, Manns M, Klompmaker IJ, Slooff MJ, Gerber MA. Is there recurrence of primary biliary cirrhosis after liver transplantation? A clinicopathologic study in long-term survivors. J Hepatol 1994 20 : 500.
16. Levitsky J, Hart J, Cohen SM, Te HS. The effect of immunosuppressive regimens on the recurrence of primary biliary cirrhosis after liver transplantation. Liver Transpl 2003 9 : 733.
17. Neuberger J, Gunson B, Hubscher S, Nightingale P. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2004 10 : 488.
18. Sanchez EQ, Levy MF, Goldstein RM, et al. The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation. Transplantation 2003 76 : 1583.
19. Sylvestre PB, Batts KP, Burgart LJ, Poterucha JJ, Wiesner RH. Recurrence of primary biliary cirrhosis after liver transplantation: Histologic estimate of incidence and natural history. Liver Transpl 2003 9 : 1086.
20. Hashimoto E, Shimada M, Noguchi S, et al. Disease recurrence after living liver transplantation for primary biliary cirrhosis: a clinical and histological follow-up study. Liver Transpl 2001 7 : 588.
21. Salguero O, Moreno JM, Seijas MC, et al. Recurrence of primary biliary cirrhosis after liver transplantation. Transplant Proc 2003 35 : 721.
22. Brandsaeter B, Schrumpf E, Bentdal O, et al. Recurrent primary sclerosing cholangitis after liver transplantation: a magnetic resonance cholangiography study with analyses of predictive factors. Liver Transpl 2005 11 : 1361.
23. Graziadei IW, Wiesner RH, Batts KP, et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 1999 29 : 1050.
24. Jeyarajah DR, Netto GJ, Lee SP, et al. Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: is chronic rejection part of the disease process? Transplantation 1998 66 : 1300.
25. Khettry U, Keaveny A, Goldar-Najafi A, et al. Liver transplantation for primary sclerosing cholangitis: a long-term clinicopathologic study. Hum Pathol 2003 34 : 1127.
26. Kugelmas M, Spiegelman P, Osgood MJ, et al. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2003 9 : 727.
27. Vera A, Moledina S, Gunson B, et al. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 2002 360 : 1943.
28. Goss JA, Shackleton CR, Farmer DG, et al. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Ann Surg 1997 225 : 472.
29. Liden H, Norrby J, Gabel M, Friman S, Olausson M. Outcome after liver transplantation for primary sclerosing cholangitis. Transplant Proc 2001 33 : 2452.
30. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999 31 : 929.
31. Ahmed M, Mutimer D, Hathaway M, Hubscher S, McMaster P, Elias E. Liver transplantation for autoimmune hepatitis: a 12-year experience. Transplant Proc 1997 29 : 496.
32. Gotz G, Neuhaus R, Bechstein WO, et al. Recurrence of autoimmune hepatitis after liver transplantation. Transplant Proc 1999 31 : 430.
33. Klein R, Huizenga JR, Gips CH, Berg PA. Antimitochondrial antibody profiles in patients with primary biliary cirrhosis before orthotopic liver transplantation and titres of antimitochondrial antibody-subtypes after transplantation. J Hepatol 1994 20 : 181.
34. Haydon GH, Neuberger J. PBC: an infectious disease? Gut 2000 47 : 586.
35. Manns MP, Bahr MJ. Recurrent autoimmune hepatitis after liver transplantation-when non-self becomes self. Hepatology 2000 32 : 868.
36. Ratziu V, Samuel D, Sebagh M, et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol 1999 30 : 131.
37. Duclos-Vallee JC, Johanet C, Bach JF, Yamamoto AM. Autoantibodies associated with acute rejection after liver transplantation for type-2 autoimmune hepatitis. J Hepatol 2000 33 : 163.
38. Lohse AW, Obermayer-Straub P, Gerken G, et al. Development of cytochrome P450 2D6-specific LKM-autoantibodies following liver transplantation for Wilson's disease - possible association with a steroid-resistant transplant rejection episode. J Hepatol 1999 31 : 149.
39. Jones DE, James OF, Portmann B, Burt AD, Williams R, Hudson M. Development of autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. Hepatology 1999 30 : 53.
40. Kerkar N, Hadzic N, Davies ET, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998 351 : 409.
41. Syn WK, Nightingale P, Gunson B, Hubscher SG, Neuberger JM. Natural history of unexplained chronic hepatitis after liver transplantation. Liver Transpl 2007 13 : 984.
42. Sanchez-Urdazpal L, Gores GJ, Ward EM, et al. Ischemic-type biliary complications after orthotopic liver transplantation. Hepatology 1992 16 : 49.
43. Sanchez-Urdazpal L, Gores GJ, Ward EM, et al. Diagnostic features and clinical outcome of ischemic-type biliary complications after liver transplantation. Hepatology 1993 17 : 605.
44. Hubscher SG. Recurrent autoimmune hepatitis after liver transplantation: diagnostic criteria, risk factors, and outcome. Liver Transpl 2001 7 : 285.
45. Milkiewicz P, Gunson B, Saksena S, Hathaway M, Hubscher SG, Elias E. Increased incidence of chronic rejection in adult patients transplanted for autoimmune hepatitis: assessment of risk factors. Transplantation 2000 70 : 477.
46. Sempoux C, Horsmans Y, Lerut J, Rahier J, Geubel A. Acute lobular hepatitis as the first manifestation of recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver 1997 17 : 311.
47. Hubscher SG. Transplantation pathology. Semin Diagn Pathol 2006 23 : 170.
48. Khapra AP, Agarwal K, Fiel MI, et al. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts. Liver Transpl 2006 12 : 1496.
49. Mohamed R, Hubscher SG, Mirza DF, Gunson BK, Mutimer DJ. Posttransplantation chronic hepatitis in fulminant hepatic failure. Hepatology 1997 25 : 1003.
50. Seyam M, Neuberger JM, Gunson BK, Hubscher SG. Cirrhosis after orthotopic liver transplantation in the absence of primary disease recurrence. Liver Transpl 2007 13 : 966.
51. Shaikh OS, Demetris AJ. Idiopathic posttransplantation hepatitis? Liver Transpl 2007 13 : 943.
52. Sundaram SS, Melin-Aldana H, Neighbors K, Alonso EM. Histologic characteristics of late cellular rejection, significance of centrilobular injury, and long-term outcome in pediatric liver transplant recipients. Liver Transpl 2006 12 : 58.
53. Hubscher SG. Central perivenulitis: A common and potentially important finding in late post-transplant liver biopsies. Liver Transpl 2008 14 : 596.
54. Krasinskas A. The prevalence and natural history of untreated central perivenulitis in adult allograft livers. Liver Transpl 2008 14 : 625.
55. Andries S, Casamayou L, Sempoux C, et al. Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine. Transplantation 2001 72 : 267.
56. Hernandez HM, Kovarik P, Whitington PF, Alonso EM. Autoimmune hepatitis as a late complication of liver transplantation. J Pediatr Gastroenterol Nutr 2001 32 : 131.
57. Heneghan MA, Portmann BC, Norris SM, et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology 2001 34 : 464.
58. Salcedo M, Vaquero J, Banares R, et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology 2002 35 : 349.
59. Aguilera I, Wichmann I, Sousa JM, et al. Antibodies against glutathione S-transferase T1 in patients with immune hepatitis after liver transplantation. Transplant Proc 2003 35 : 712.
60. Aguilera I, Sousa JM, Gavilan F, Bernardos A, Wichmann I, Nunez-Roldan A. Glutathione S-transferase T1 genetic mismatch is a risk factor for de novo immune hepatitis in liver transplantation. Transplant Proc 2005 37 : 3968.
61. D'Antiga L, Dhawan A, Portmann B, et al. Late cellular rejection in paediatric liver transplantation: aetiology and outcome. Transplantation 2002 73 : 80.
62. Miyagawa-Hayashino A, Haga H, Sakurai T, Shirase T, Manabe T, Egawa H. De novo autoimmune hepatitis affecting allograft but not the native liver in auxiliary partial orthotopic liver transplantation. Transplantation 2003 76 : 271.
63. Rodriguez-Mahou M, Salcedo M, Fernandez-Cruz E, et al. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with GSTT1 null genotype as prognostic marker: long-term follow-up after liver transplantation. Transplantation 2007 83 : 1126.
64. Mieli-Vergani G, Vergani D. De novo autoimmune hepatitis after liver transplantation. J Hepatol 2004 40 : 3.
65. Berardi S, Lodato F, Gramenzi A, et al. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Gut 2007 56 : 237.
66. Cholongitas E, Samonakis D, Patch D, et al. Induction of autoimmune hepatitis by pegylated interferon in a liver transplant patient with recurrent hepatitis C virus. Transplantation 2006 81 : 488.
67. Kontorinis N, Agarwal K, Elhajj N, Fiel MI, Schiano TD. Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation. Liver Transpl 2006 12 : 827.
68. Stanca CM, Fiel MI, Kontorinis N, Agarwal K, Emre S, Schiano TD. Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin. Transplantation 2007 84 : 180.
69. Walter T, Dumortier J, Guillaud O, et al. Rejection under alpha interferon therapy in liver transplant recipients. Am J Transplant 2007 7 : 177.
70. Bucy RP, Xu XY, Li J, Huang G. Cyclosporin A-induced autoimmune disease in mice. J Immunol 1993 151 : 1039.
71. Gao EK, Lo D, Cheney R, Kanagawa O, Sprent J. Abnormal differentiation of thymocytes in mice treated with cyclosporin A. Nature 1988 336 : 176.
72. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000 101 : 455.
73. Sakaguchi S, Sakaguchi N. Role of genetic factors in organ-specific autoimmune diseases induced by manipulating the thymus or T cells, and not self-antigens. Rev Immunogenet 2000 2 : 147.
74. Garcia-Buey L, Garcia-Monzon C, Rodriguez S, et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995 108 : 1770.
75. Miyagawa-Hayashino A, Haga H, Egawa H, et al. Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation. Transplantation 2004 78 : 128.
76. Riva S, Sonzogni A, Bravi M, et al. Late graft dysfunction and autoantibodies after liver transplantation in children: preliminary results of an Italian experience. Liver Transpl 2006 12 : 573.
77. Aguilera I, Wichmann I, Sousa JM, et al. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with de novo immune hepatitis following liver transplantation. Clin Exp Immunol 2001 126 : 535.
78. Yoshizawa K, Shirakawa H, Ichijo T, et al. De novo autoimmune hepatitis following living-donor liver transplantation for primary biliary cirrhosis. Clin Transplant 2008 22 : 385.
79. Charatcharoenwitthaya P, Pimentel S, Talwalkar JA, et al. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2007 13 : 1236.
80. Pardi DS, Loftus EV Jr., Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003 124 : 889.
81. Hurtova M, Duclos-Vallee JC, Johanet C, et al. Successful tacrolimus therapy for a severe recurrence of type 1 autoimmune hepatitis in a liver graft recipient. Liver Transpl 2001 7 : 556.
82. Dvorchik I, Subotin M, Demetris AJ, et al. Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology 2002 35 : 380.
83. Cholongitas E, Shusang V, Papatheodoridis GV, et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2008 14 : 138.
84. Alexander J, Lord JD, Yeh MM, Cuevas C, Bakthavatsalam R, Kowdley KV. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2008 14 : 245.
85. Boberg KM, Spurkland A, Rocca G, et al. The HLA-DR3,DQ2 heterozygous genotype is associated with an accelerated progression of primary sclerosing cholangitis. Scand J Gastroenterol 2001 36 : 886.
86. O'Mahony CA, Vierling JM. Etiopathogenesis of primary sclerosing cholangitis. Semin Liver Dis 2006 26 : 3.
87. Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev 2000 174 : 250.
88. Donaldson PT, Czaja AJ. Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 autoimmune hepatitis. Clin Liver Dis 2002 6 : 707.
89. Cookson S, Constantini PK, Clare M, et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology 1999 30 : 851.
90. Vierling JM. Immunology of acute and chronic hepatic allograft rejection. Liver Transpl Surg 1999 5 : S1.
91. Van de Water J, Gerson LB, Ferrell LD, et al. Immunohistochemical evidence of disease recurrence after liver transplantation for primary biliary cirrhosis. Hepatology 1996 24 : 1079.